Skip to content

ImmunityBio, Inc. IBRX Prepaid software license fees

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept ibrx:PrepaidSoftwareLicenseFees.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s prepaid software license fees.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s prepaid software license fees?
ImmunityBio, Inc. (IBRX) reported prepaid software license fees of $4.36M in Q1 2026.
How has ImmunityBio, Inc.'s prepaid software license fees changed year-over-year?
ImmunityBio, Inc.'s prepaid software license fees increased by 62.3% year-over-year, from $2.68M to $4.36M.
What is the long-term trend for ImmunityBio, Inc.'s prepaid software license fees?
Over 4 years (2021 to 2025), ImmunityBio, Inc.'s prepaid software license fees has grown at a 34.1% compound annual growth rate (CAGR), from $1.11M to $3.59M.